✦ LIBER ✦

Imatinib mesylate: response in hypereosinophilic syndrome

Book ID: 120860809
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2003
Weight: 139 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200313810-00016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Response to imatinib mesylate in patient

Response to imatinib mesylate in patients with hypereosinophilic syndrome

✍ Maryam Arefi,Juan L. García,M. Montserrat Briz… 📂 Article 📅 2012 🏛 Carden Jennings Publishing 🌐 English ⚖ 194 KB

Imatinib mesylate may induce long-term c

Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome

✍ Grzegorz Helbig, Marek Hus, Magdalena Hałasz, Marek Dudziński, Agnieszka Więcław 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 167 KB

Response to Imatinib Mesylate in a Patie

Response to Imatinib Mesylate in a Patient with Idiopathic Hypereosinophilic Syndrome Associated with Cyclic Eosinophil Oscillations

✍ Shinsaku Imashuku; Naoki Kakazu; Ikuyo Ueda; Akira Morimoto; Hironori Harada; To 📂 Article 📅 2005 🏛 Carden Jennings Publishing 🌐 English ⚖ 728 KB

Success of short-term, higher-dose imati

Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome

✍ Joseph H. Butterfield 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 209 KB

Hypereosinophilic syndrome and effect of

Hypereosinophilic syndrome and effect of imatinib mesylate

✍ Richard A. Kerensky; Sony Jacob; Richard J. Kovacs 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 51 KB

Imatinib mesylate for lymphocytic varian

Imatinib mesylate for lymphocytic variant of hypereosinophilic syndrome: A response

✍ Anna Christoforidou 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 604 KB

## Imatinib mesylate for lymphocytic variant of hypereosinophilic syndrome To the editor: With a great interest I read a paper by Christoforidou et al. [1] showing the high efficacy of imatinib mesylate (IM) in a patient with L-HES and undetectable FIP1L1-PDGFRA (F/P) fusion transcript. However, a